Guerbet is releasing the first production batch of its Elucirem (gadopiclenol) injection, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI.
The company said this agent is "highly stable" and has relaxivity in its class for MRI. It is indicated for use in adults and children aged two and older.
The injection is used to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. Guerbet said the gadopiclenol in the injection has been designed to allow for twice as much interaction, meaning higher relaxivity and less gadolinium dosage.
